Cargando…
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
INTRODUCTION: The aim of this study was to determine the efficacy of early tocilizumab treatment for hospitalized patients with COVID-19 disease. METHODS: Open-label randomized phase II clinical trial investigating tocilizumab in patients with proven COVID-19 admitted to the general ward and in need...
Autores principales: | Rutgers, Abraham, Westerweel, Peter E., van der Holt, Bronno, Postma, Simone, van Vonderen, Marit G. A., Piersma, Djura P., Postma, Douwe, van den Berge, Maarten, Jong, Eefje, de Vries, Marten, van der Burg, Leonie, Huugen, Dennis, van der Poel, Marjolein, Kampschreur, Linda M., Nijland, Marcel, Strijbos, Jaap H., Tamminga, Menno, Mutsaers, Pim G. N. J., Schol-Gelok, Suzanne, Dijkstra-Tiekstra, Margriet, Sidorenkov, Grigory, Vincenten, Julien, van Geffen, Wouter H., Knoester, Marjolein, Kosterink, Jos, Gans, Reinold, Stegeman, Coen, Huls, Gerwin, van Meerten, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374226/ https://www.ncbi.nlm.nih.gov/pubmed/35960720 http://dx.doi.org/10.1371/journal.pone.0271807 |
Ejemplares similares
-
Starting Home Telemonitoring and Oxygen Therapy Directly after Emergency Department Assessment Appears to Be Safe in COVID-19 Patients
por: van den Berg, Rosaline, et al.
Publicado: (2022) -
Clinical effects of antiplatelet drugs and statins on D‐dimer levels
por: Schol‐Gelok, Suzanne, et al.
Publicado: (2018) -
Improved diagnostic policy for respiratory tract infections essential for patient management in the emergency department
por: Poelman, Randy, et al.
Publicado: (2020) -
Exploring the Quality Paradigms in Integrated Care: The Need for Emergence and Reflection
por: van Kemenade, Everard, et al.
Publicado: (2021) -
Zoonotic Transmission of Vaccine-Derived Bordetella bronchiseptica
por: Kraai, Imke, et al.
Publicado: (2023)